TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04218357

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probenecid
Description: safety

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo
Description: Placebo
Study: NCT03564405

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: UNI-DEB
Description: Applicate the TACE with UNI-DEB to unresectable hepatocellular carcinoma patient
Study: NCT02485431

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deflazacort
Study: NCT00074373

Intervention type: OTHER
Intervention: No intervention; observational
Study: NCT01352741

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tapentadol Prolonged Release
Description: 100 - 500 mg per day orally twice daily for a maximum of 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tapentadol Prolonged Release with Pregabalin
Description: Tapentadol Prolonged Release 100 - 300 mg per day with Pregabalin 150 - 300 mg per day orally twice daily for a maximum of 12 weeks
Study: NCT01352741

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tapentadol Prolonged Release open label maintenance
Description: 100 - 400 mg per day Tapentadol Prolonged Release orally administered twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tapentadol Prolonged Release open label maintenance
Description: 100 - 400 mg per day Tapentadol Prolonged Release orally administered twice daily
Study: NCT04006990

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Provision of recliner chairs and encouragement to get out of bed
Description: Provision of recliner chairs and encouragement to get out of bed
Study: NCT03589365

Intervention type: OTHER
Group type: OTHER
Intervention: Magnetic resonance imaging (MRI)
Description: Compare the left ventricular mass of a young adult population born prematurely (Prema group) to that of a group of young adults born at term (Witness group~The measurements made during this examination are:~Coronary Reserve Presence of fat in the myocardium Left ventricular mass Left ventricular volume~The measurements made during this examination are:~Coronary Reserve Presence of fat in the myocardium Left ventricular mass Left ventricular volume

Intervention type: OTHER
Group type: OTHER
Intervention: Magnetic resonance imaging (MRI)
Description: Compare the left ventricular mass of a young adult population born prematurely (Prema group) to that of a group of young adults born at term (Witness group~The measurements made during this examination are:~Coronary Reserve Presence of fat in the myocardium Left ventricular mass Left ventricular volume~The measurements made during this examination are:~Coronary Reserve Presence of fat in the myocardium Left ventricular mass Left ventricular volume
Study: NCT02282371

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BYL719

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT (Intensity-Modulated Radiation Therapy)
Study: NCT02463032

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GTx-024
Description: To determine whether either or both doses result in an acceptable clinical benefit rate.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GTx-024
Description: To determine whether either or both doses result in an acceptable clinical benefit rate.
Study: NCT01257490

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: counseling vs. advice
Description: 1 session of brief physician advice to quit smoking plus bupropion (12 weeks) compared to 4 sessions of intensive counseling plus bupropion (12 weeks)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: counseling vs. advice
Description: 1 session of brief physician advice to quit smoking plus bupropion (12 weeks) compared to 4 sessions of intensive counseling plus bupropion (12 weeks)
Study: NCT04503590

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Minimally Invasive Micro Sclerostomy (MIMS)
Description: The System is a surgical device, designed to create a drainage channel at the sclera-corneal junction . The drainage channel is created by a Stainless Steel surgical tool.
Study: NCT02448953

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Two-field lymphadenectomy
Description: Thoracic-upper abdominal two-field lymphadenectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Three-field lymphadenectomy
Description: Cervical-thoracic-upper abdominal three-field completely lymphadenectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Three-field lymphadenectomy
Description: Cervical-thoracic-upper abdominal three-field completely lymphadenectomy
Study: NCT00574665

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hyperinsulinemic Hyperglycemic Clamp
Description: Glucose Clamp
Study: NCT00060814

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combined intervention
Description: 300 mg bupropion plus 4mg nicotine gum ad lib plus motivational interviewing counseling
Study: NCT04070196

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Periplex
Description: Periplex test strip will be used to examine the PD effluent for peritonitis, in addition to the routine leucocyte testing of PD effluent
Study: NCT03918226

Intervention type: PROCEDURE
Group type: OTHER
Intervention: exploratory laparotomy
Description: Patients presenting with acute abdomen were operated. Exploratory Laparotomy of patients was done. Further procedure was done according to peroperative findings. Ileostomy for perforation of gut, stricturoplasty for strictutre, biopsy for mesentric lymphadenopathy
Study: NCT00383734

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Newfill
Description: 1 to 7 injections of drug

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Eutrophill
Description: 1 to 7 injections of drug
Study: NCT04363593

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Serological test
Description: Serological testing is performed for patients with confirmed COVID-19 infection by RT-PCR.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Serological test
Description: Serological testing is performed for patients with confirmed COVID-19 infection by RT-PCR.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Serum test
Description: Use of the serum taken from patients consulted for suspicion of COVID-19 before the beginning of the trial

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Serum test
Description: Use of the serum taken from patients consulted for suspicion of COVID-19 before the beginning of the trial
Study: NCT03553498

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV acetaminophen
Description: acetaminophen given intravenously

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IV placebo
Description: given intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydromorphone
Description: hydromorphone given intravenously
Study: NCT02677766

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: occupational therapy
Description: an intervention phase in the period of hospitalization for rehabilitation in the hospital, aimed mainly at achieving objectives related to the area of self-care and, secondly, the objectives in the areas of productivity and leisure, identified at T0; plus an intervention in the post-discharge at the patient's home, aimed primarily at achieving objectives related to the areas of productivity and leisure time and, secondly, to possible targets in residues of self-care, identified in T0.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Usual care consists in rehabilitation treatment delivered by a multidisciplinary team
Study: NCT04131556

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maribavir
Description: Participants in both part 1 and part 2 of the study will receive maribavir tablet or suspension orally depending upon the treatment sequence allocation for a total of 7 and 10 days respectively.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maribavir
Description: Participants in both part 1 and part 2 of the study will receive maribavir tablet or suspension orally depending upon the treatment sequence allocation for a total of 7 and 10 days respectively.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maribavir
Description: Participants in both part 1 and part 2 of the study will receive maribavir tablet or suspension orally depending upon the treatment sequence allocation for a total of 7 and 10 days respectively.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maribavir
Description: Participants in both part 1 and part 2 of the study will receive maribavir tablet or suspension orally depending upon the treatment sequence allocation for a total of 7 and 10 days respectively.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maribavir
Description: Participants in both part 1 and part 2 of the study will receive maribavir tablet or suspension orally depending upon the treatment sequence allocation for a total of 7 and 10 days respectively.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maribavir
Description: Participants in both part 1 and part 2 of the study will receive maribavir tablet or suspension orally depending upon the treatment sequence allocation for a total of 7 and 10 days respectively.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maribavir
Description: Participants in both part 1 and part 2 of the study will receive maribavir tablet or suspension orally depending upon the treatment sequence allocation for a total of 7 and 10 days respectively.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maribavir
Description: Participants in both part 1 and part 2 of the study will receive maribavir tablet or suspension orally depending upon the treatment sequence allocation for a total of 7 and 10 days respectively.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maribavir
Description: Participants in both part 1 and part 2 of the study will receive maribavir tablet or suspension orally depending upon the treatment sequence allocation for a total of 7 and 10 days respectively.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maribavir
Description: Participants in both part 1 and part 2 of the study will receive maribavir tablet or suspension orally depending upon the treatment sequence allocation for a total of 7 and 10 days respectively.
Study: NCT00664599

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Infusion of Rituximab, 1500 mg, two times with 15 days interval. Patients receive also Methotrexate (15 mg weekly) and Prednisolone (0.5 mg/daily).
Study: NCT03553498

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: hydromorphone
Description: hydromorphone given intravenously
Study: NCT02156817

Intervention type: OTHER
Intervention: Amplitude integrated electroencephalogram, Cardiorespiratory signal acquisition

Intervention type: OTHER
Intervention: Amplitude integrated electroencephalogram, Cardiorespiratory signal acquisition
Study: NCT00047619

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulsatile Lavage
Description: pulsatile lavage to wound bed

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham pulsatile lavage
Description: pulsatile lavage to not directed at wound or patient
Study: NCT01922063

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physiotherapy Intervention
Description: 20x 30 min sessions of physiotherapy

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham neck massage
Description: 20x 30 minutes sessions of neck massage
Study: NCT01912157

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Expressive Writing
Description: The intervention consists in 3 self-applied solitary written disclosure sessions (expressive writing)

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Expressive Writing
Description: The intervention consists in 3 self-applied solitary written disclosure sessions (expressive writing)
Study: NCT00846040

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reduced fat diet
Description: RF (selective reduction of 85% of baseline fat calories per day)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reduced fat diet
Description: RF (selective reduction of 85% of baseline fat calories per day)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reduced carbohydrate diet
Description: RC (selective reduction of 60% of baseline carbohydrate calories per day)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reduced carbohydrate diet
Description: RC (selective reduction of 60% of baseline carbohydrate calories per day)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Drug: f-18 fallypride
Description: Dopamine D2 receptor availability is measured by positron emission tomography (PET) using the positron emitting compound \[18F\] fallypride which binds competitively with dopamine to the D2 receptor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: f-18 fallypride
Description: Dopamine D2 receptor availability is measured by positron emission tomography (PET) using the positron emitting compound \[18F\] fallypride which binds competitively with dopamine to the D2 receptor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: f-18 fallypride
Description: Dopamine D2 receptor availability is measured by positron emission tomography (PET) using the positron emitting compound \[18F\] fallypride which binds competitively with dopamine to the D2 receptor.
Study: NCT03433391

Intervention type: DEVICE
Group type: OTHER
Intervention: Oxiplex
Description: Oxiplex is a clear, viscoelastic gel that is applied to operative site during lumbar spine surgery in order to coat the nerve root with a protective barrier.
Study: NCT00846040

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: fMRI
Description: Functional MRI (fMRI) will be used to measure the effects of diet and weight loss on regional brain activity

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: fMRI
Description: Functional MRI (fMRI) will be used to measure the effects of diet and weight loss on regional brain activity

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: fMRI
Description: Functional MRI (fMRI) will be used to measure the effects of diet and weight loss on regional brain activity

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PET
Description: Positron emission tomography (PET) will be used to assess whether To assess whether brain activity and reward pathways are altered

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET
Description: Positron emission tomography (PET) will be used to assess whether To assess whether brain activity and reward pathways are altered

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET
Description: Positron emission tomography (PET) will be used to assess whether To assess whether brain activity and reward pathways are altered
Study: NCT02904122

Intervention type: OTHER
Group type: OTHER
Intervention: teleconsultation
Description: Determine the interest of teleconsultation in dentistry tool for the diagnosis of caries. Ie whether oral teleconsultations are of the same quality as conventional consultations for the diagnosis of caries ..
Study: NCT03433391

Intervention type: OTHER
Group type: OTHER
Intervention: Surgery Only
Description: Single level partial discectomy as per standard of care procedures.
Study: NCT03200418

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard hydrocolloid adhesive
Description: This patch is made of standard hydrocolloid adhesive

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: P-4
Description: This patch is made of new adhesive

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: P-15
Description: This patch is made of new adhesive

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: P-16
Description: This patch is made of new adhesive
Study: NCT03624959

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ozanimod
Description: ozanimod

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ozanimod
Description: ozanimod

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ozanimod
Description: ozanimod

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ozanimod
Description: ozanimod

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ozanimod
Description: ozanimod

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemfibrozil
Description: Gemfibrozil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Itraconazole
Study: NCT01044316

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Haemophilus influenzae type b (Hib) vaccine
Description: Comparator study of two commercially available Haemophilus influenzae type b (Hib) vaccines - a monovalent glycoprotein-conjugated (diptheria toxin - CRM197) vaccine and a tetanus toxoid-conjugated vaccine.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Haemophilus influenzae type b (Hib) vaccine
Description: Comparator study of two commercially available Haemophilus influenzae type b (Hib) vaccines - a monovalent glycoprotein-conjugated (diptheria toxin - CRM197) vaccine and a tetanus toxoid-conjugated vaccine.
Study: NCT01898104

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: preoperative radiation therapy
Description: 25 Gy in 5 fractions over 1 week
Study: NCT04202029

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: thoracic impedance monitoring
Description: Thoracic impedance measurement identifies the respiratory frequence using the changes of impedance during inspiration and expiration via an ECG.
Study: NCT01898104

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: preoperative radiation therapy
Description: 25 Gy in 5 fractions over 1 week

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: preoperative radiation therapy
Description: 25 Gy in 5 fractions over 1 week

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: preoperative radiation therapy
Description: 25 Gy in 5 fractions over 1 week

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valproic Acid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valproic Acid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Study: NCT04202029

Intervention type: DEVICE
Group type: OTHER
Intervention: pulseoxymetry
Description: Pulseoxymetry is meassuring the heart rate and the oxygen saturation in the arterial blood

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pulseoxymetry
Description: Pulseoxymetry is meassuring the heart rate and the oxygen saturation in the arterial blood

Intervention type: DEVICE
Group type: OTHER
Intervention: non-invasive blood preassure monitoring
Description: Non-invasive blood preassure is a method using a blood preassure cuff to identify the blood preassure.
Study: NCT03958591

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CSII and thereafter combination therapy, followed up with wearable devices
Description: Short-term continuous subcutaneous insulin infusion and thereafter the combination therapy of basal insulin, metformin and vildagliptin; Wearable devices and smart apps will be used to manage and follow-up the participants.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CSII and thereafter combination therapy, followed up in traditional ways
Description: Short-term continuous subcutaneous insulin infusion and thereafter the combination therapy of basal insulin, metformin and vildagliptin; Traditional ways such as telephone contact will be used for follow up.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Traditionally upgrading therapy, followed up in traditional ways
Description: The participants will be applied the combination therapy of basal insulin, metformin and vildagliptin for the entire 12 weeks. Traditional ways will be used for follow up.
Study: NCT03596073

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical Calcipotriene Ointment
Description: Calcipotriene is a form of vitamin D. It works by slowing down the growth of skin cells.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Topical Vaseline
Description: Placebo
Study: NCT03971604

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin A
Description: treated with Vitamin A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin A
Description: treated with Vitamin A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin E
Description: treated with Vitamin E

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin E
Description: treated with Vitamin E
Study: NCT03674099

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib Mesylate
Description: Tablets 400 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: 1 g tablets or infusion
Study: NCT05661305

Intervention type: OTHER
Intervention: Whole Genome Sequencing to compare healthy volunteers genome with that of cardiomyopathies patients.
Description: Egyptian patients and their family members diagnosed with different types hereditary cardiomyopathies.Healthy Egyptian individuals to provide the first of its kind resource on human genetic variation in Egyptians, which is essential for understanding the significance of detected variations in patients with inherited cardiovascular disease and their families.

Intervention type: OTHER
Intervention: Whole Genome Sequencing to compare healthy volunteers genome with that of cardiomyopathies patients.
Description: Egyptian patients and their family members diagnosed with different types hereditary cardiomyopathies.Healthy Egyptian individuals to provide the first of its kind resource on human genetic variation in Egyptians, which is essential for understanding the significance of detected variations in patients with inherited cardiovascular disease and their families.
Study: NCT02446873

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Egg supplementation
Description: A weekly supply of eggs will be given to the mother in the egg supplementation group with instructions to give the child one egg per day.
Study: NCT04970160

Intervention type: PROCEDURE
Intervention: TSARP
Description: We make four different surgical operations for female patients with rectovestibular fistula

Intervention type: PROCEDURE
Intervention: PSARP
Description: Posterior sagittal anorectoplasty
Study: NCT04202029

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: non-invasive blood preassure monitoring
Description: Non-invasive blood preassure is a method using a blood preassure cuff to identify the blood preassure.